Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Diageo plc (DEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Diageo plc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $360.13 (market cap $9.43B), while Diageo plc trades at $93.51 (market cap $53.05B). The key difference: Diageo plc is far larger — about 5.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Diageo plc pays a 3.5% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | DEO | |
|---|---|---|
Market Cap | $9.43B | $53.05B |
Sector | Health | Technology |
52-Week High | $356.25 | $115.33 |
52-Week Low | $241.71 | $72.47 |
Enterprise Value | $9.18B | $72.54B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Diageo (DEO) trades at $93.47, down 3.75% on the day, amid mixed earnings and a $1 billion cost-cutting plan announced in August 2026. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentals reveal a P/E of 30.47, net income margin of 8.84%, and recent earnings beats in Q4 2025 and Q2 2026, offset by a Q2 2025 miss. Revenue dipped to $19.6 billion in 2026, with North America weakness pressuring results.
The outlook is cautiously optimistic, driven by cost savings and strategic shifts under CEO Dave Lewis, but risks include regional sales volatility and high debt. Analyst consensus leans buy (48.65%), with price targets suggesting upside, though execution on the turnaround plan is critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
